A strategic investor purchased 8% total shares outstanding of Medigen Vaccinology Corp., a Medgien subsidiary. 

Medigen's board of directors has agreed to sell 4 million shares, equal to 8% of total outstanding shares, of Medigen Vaccinology Corp., a Medgien subsidiary, to a strategic investor for total proceeds of NT$120M.